Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 149

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 149
---
:---------|:----|:--------------------|:----|:------|
| Public offering price            |     | $        |     | $                   |     | $     |
| Placement agent fees             |     | $        |     | $                   |     | $     |
| Proceeds, before expenses, to us |     | $        |     | $                   |     | $     |

Placement Agent Warrants

The placement agent has committed to purchase Placement Agent Warrants
to purchase up to a number of Depositary Shares equal to 5.0% of the units sold in this offering for $1.995 per warrant. The Placement
Agent Warrants will have an exercise price equal to 225% of the offering price per Unit, subject to customary anti-dilution provisions
consistent with FINRA Rule 5110(g)(8). The Placement Agent Warrants will be substantially similar to the Series L Warrants issued hereunder.
As with the Series L Warrants, the Placement Agent Warrants will expire two and a half (2.5) years after the issuance date and do not
provide for any registration rights. The Placement Agent Warrants and the Depositary Shares (representing Ordinary Shares) are being registered
on the registration statement of which this prospectus is a part.

If all of the Placement Agents Warrants
are exercised on a zero cash exercise price basis at the floor price, an aggregate of 253,282,500,000 Ordinary Shares (in the form of
Depositary Shares) would be issued upon such zero cash exercise without payment to the Company of any additional cash.

| 86 |

The Placement Agent Warrants and underlying
shares have been deemed compensation by FINRA. Pursuant to FINRA Rule 5110(e)(1), underwriting compensation consisting of securities must
not be sold, transferred, assigned, pledged or hypothecated nor may they be the subject of any hedging, short sale, derivative, put or
call transaction that would result in the economic disposition of the securities by any person for a period of 180 days following the
commencement of sales of this offering except to any placement agent and selected dealer participating in the offering and their officers
or partners, registered persons or affiliates or as otherwise permitted under FINRA Rule 5110(e)(2). Pursuant to FINRA Rule 5110(e)(2)(A)(iii),
the Placement Agent Warrants meet an exception to the lock-up restriction under Rule 5110(e)(